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Abstract
Background: Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or
HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance
represents a major hurdle. This study was performed to analyze the RANK pathway contribution in HER2-positive
breast cancer and anti-HER2 therapy resistance.
Methods: RANK and RANKL protein expression was assessed in samples from HER2-positive breast cancer patients
resistant to anti-HER2 therapy and treatment-naive patients. RANK and RANKL gene expression was analyzed in
paired samples from patients treated with neoadjuvant dual HER2-blockade (lapatinib and trastuzumab) from the
SOLTI-1114 PAMELA trial. Additionally, HER2-positive breast cancer cell lines were used to modulate RANK
expression and analyze in vitro the contribution of RANK signaling to anti-HER2 resistance and downstream
signaling.
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Results: RANK and RANKL proteins are more frequently detected in HER2-positive tumors that have acquired resistance to
anti-HER2 therapies than in treatment-naive ones. RANK (but not RANKL) gene expression increased after dual anti-HER2
neoadjuvant therapy in the cohort from the SOLTI-1114 PAMELA trial. Results in HER2-positive breast cancer cell lines
recapitulate the clinical observations, with increased RANK expression observed after short-term treatment with the HER2
inhibitor lapatinib or dual anti-HER2 therapy and in lapatinib-resistant cells. After RANKL stimulation, lapatinib-resistant cells
show increased NF-κB activation compared to their sensitive counterparts, confirming the enhanced functionality of the
RANK pathway in anti-HER2-resistant breast cancer. Overactivation of the RANK signaling pathway enhances ERK and NF-κB
signaling and increases lapatinib resistance in different HER2-positive breast cancer cell lines, whereas RANK loss sensitizes
lapatinib-resistant cells to the drug. Our results indicate that ErbB signaling is required for RANK/RANKL-driven activation of
ERK in several HER2-positive cell lines. In contrast, lapatinib is not able to counteract the NF-κB activation elicited after RANKL
treatment in RANK-overexpressing cells. Finally, we show that RANK binds to HER2 in breast cancer cells and that enhanced
RANK pathway activation alters HER2 phosphorylation status.
Conclusions: Our data support a physical and functional link between RANK and HER2 signaling in breast cancer and
demonstrate that increased RANK signaling may contribute to the development of lapatinib resistance through NF-κB
activation. Whether HER2-positive breast cancer patients with tumoral RANK expression might benefit from dual HER2 and
RANK inhibition therapy remains to be elucidated.
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Background
The human epidermal growth factor receptor 2 (HER2),
known as ErbB2 or Neu, is a tyrosine kinase receptor protein
encoded by the ERBB2 (HER2) gene [1]. HER2 is a member
of the epidermal growth factor (EGF) receptor family along
with EGFR/HER1, ERBB3/HER3, and ERBB4/HER4. The
four receptors are transmembrane proteins with an intracel-
lular tyrosine kinase domain (although ERBB3/HER3 is con-
sidered kinase impaired). While HER2 is the only family
member that does not bind to a ligand, it forms heterodi-
mers with the other EGF receptor protein members and
shows strong catalytic kinase activity, efficiently triggering
downstream signaling through phosphatidylinositol-3 kinase
(PI3K) and mitogen-activated protein kinase (MAPK) [1].
Approximately 15–20% of primary breast cancers show
HER2 protein overexpression and/or HER2 gene amplifica-
tion [2], which is associated with poor prognosis. The devel-
opment of humanized monoclonal antibodies binding the
extracellular domain of HER2 (e.g., trastuzumab, pertuzu-
mab), EGFR-HER2 small molecule kinase inhibitors (e.g.,
lapatinib, neratinib, or tucatinib), and antibody-drug conju-
gates (e.g., T-DM1 or DS-8201) has revolutionized HER2-
positive breast cancer treatment [3]. Still, most patients with
metastatic disease eventually progress on anti-HER2 therapy
due to de novo or acquired resistance, and 20–30% of
patients with early HER2+ breast cancer relapse [4–6].
Therefore, elucidating the mechanisms of resistance to anti-
HER2 drugs is pivotal to further improve patients’ survival
outcomes.
Receptor activator of nuclear factor kappa-Β ligand
(RANKL) and its receptor (RANK) belong to the TNF
superfamily. The fundamental role of RANK signaling in
osteoporosis and bone metastasis inspired the
development of denosumab, a monoclonal antibody
against RANKL, for the treatment of skeletal-related
events (SREs) linked to osteoporosis and cancer [7].
RANK signaling activation in the breast epithelium pro-
motes tumor initiation, progression, and metastatic
spread. Thus, RANK and RANKL have emerged as
promising targets for breast cancer prevention and treat-
ment [8]. RANKL is expressed in progesterone receptor-
positive cells and acts as a paracrine mediator of proges-
terone in the mammary epithelia [9, 10]. Increased
RANK receptor expression is more frequent in hormone
receptor-negative tumors and high-grade breast cancer,
but it is also found in a subset of luminal tumors [11,
12]. RANK signaling controls proliferation and stemness
in BRCA1-mutant and oncogene-driven mammary tu-
mors [13, 14]. Interestingly, RANK signaling inhibition
has been shown to reduce HER2 tumorigenesis in pre-
clinical studies [9, 15]. In human tumors, RANKL and
HER2 levels predict metastasis to the bone in breast can-
cer better than RANKL alone [16].
Some of the common (intrinsic or acquired) resistance
mechanisms to trastuzumab and/or lapatinib treatment
are impaired HER2 binding, parallel/downstream path-
way activation, ER signaling, cell cycle de-regulation, or
escape from antibody-dependent cellular cytotoxicity
(ADCC) [17]. Personalized treatment of HER2-positive
breast cancer and better predictive biomarkers to antici-
pate therapy resistance will contribute to the identifica-
tion of patients that will benefit from new combinatorial
therapies, paving the way for HER2-positive breast can-
cer precision medicine [18].
In this study, we unveiled a functional relationship be-
tween RANK and HER2 signaling using HER2-positive
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breast cancer patient samples and cell lines. Upon ana-
lyses of HER2-positive breast cancer samples from
treatment-naive patients and residual disease at surgery
after neoadjuvant anti-HER2 therapy, including paired
samples from the phase II SOLTI-1114 PAMELA trial,
we observed that anti-HER2 treatment or resistance to
anti-HER2 therapy both resulted in increased RANK ex-
pression. Additionally, when we analyzed the effects of
RANK modulation on anti-HER2 treatment in HER2-
positive breast cancer cell lines, we observed that en-




RANK and RANKL expression was assessed in tumor
samples from three different cohorts of patients with
HER2-positive breast cancer.
Treatment-naive cohort
Patients with primary and operable HER2-positive breast
cancer (n = 197) diagnosed from 2003 to 2010 at the
Nottingham City Hospital, Nottingham, UK. Tumor
samples were collected at surgery prior to any neoadju-
vant treatment. Histological grade was assessed by the
Nottingham Grading System [19] and other clinicopath-
ological factors such as tumor size, lymph node (LN)
status, estrogen receptor (ER), progesterone receptor
(PR), and HER2 expression, as well as patient age and
disease progression, were analyzed before including the
samples into the TMAs, prepared as previously de-
scribed [20].
Anti-HER2-resistant cohort
Patients treated with trastuzumab-based primary chemo-
therapy and residual disease at surgery (n = 43) diag-
nosed at the Catalan Institute of Oncology (ICO),
Bellvitge University Hospital in l’Hospitalet de Llobregat,
and Dr. Josep Trueta University Hospital in Girona
(Spain) between 2005 and 2014 and described in [21].
The selection criterion included patients with early or
locally advanced HER2-positive breast cancer (including
inflammatory breast cancer) who had received neoadju-
vant treatment with trastuzumab-based chemotherapy
and had residual invasive disease following surgery (i.e.,
who had not achieved a pathological complete response
at surgery). Neoadjuvant chemotherapy was based on
anthracyclines and taxanes given concurrently with
weekly trastuzumab for 24 weeks followed by surgery.
For all patients, hematoxylin and eosin (H&E)-stained
slides from formalin-fixed paraffin-embedded (FFPE)
tumor blocks were examined to determine representa-
tive areas of the invasive tumor. ER, PR, and HER2 posi-
tivity were assessed in the initial tumor core biopsies as
well as in the residual disease. For each patient, different
clinical and histopathological features such as age, and
histological grade (Nottingham Grading System) were
obtained.
SOLTI-1114 PAMELA cohort
Patients treated with neoadjuvant dual-blockade trastuzu-
mab and lapatinib (n = 151) and in which biopsy paired
samples were prospectively obtained. The main results of
the PAMELA neoadjuvant phase II study have been previ-
ously reported [22] and the completed study is registered
in ClinicalTrials.gov (number NCT01973660). In this trial,
patients with early HER2-positive breast cancer were
treated with neoadjuvant lapatinib (1000mg daily) and
trastuzumab (8mg/kg i.v. loading dose followed by 6mg/
kg) for 18 weeks. Patients with hormonal receptor-positive
breast cancer received letrozole or tamoxifen according to
menopausal status. FFPE tumor samples at baseline, at
day 14 of treatment, and at surgery were collected accord-
ing to standard protocols.
Gene expression analyses
RNA samples of the PAMELA trial from tumors at base-
line (n = 151) were previously analyzed [22]. Here, the
nCounter platform (NanoString Technologies, Seattle,
WA, USA) analyzed RNA of 101 residual tumors from
surgical samples of the PAMELA trial. A minimum of
100 ng of total RNA was used to measure the expression
of 550 genes, including RANK and RANKL, and 5 house-
keeping genes (ACTB, MRPL19, PSMC4, RPLP0, and
SF3A1). Expression counts were then normalized using
the the nSolver 4.0 software and custom scripts in R
3.4.3. For each sample, we calculated the PAM50 signa-
ture scores (basal-like, HER2-E, luminal A and B,
normal-like) and the risk of recurrence score [23]. In-
trinsic molecular subtypes were identified using the
research-based PAM50 predictor as previously described
[22, 24].
Immunohistochemistry and tissue microarray scoring
Immunohistochemistry (IHC) in TMAs was performed
using anti-human mouse monoclonal RANK (N-1H8
Amgen) and human RANKL (M366 Amgen) as de-
scribed in [9]. RANK or RANKL staining was scored on
a scale of 0 to 3 for intensity (0 = no staining, 1 = weak,
2 =moderate, 3 = intense) and for the percentage of
positively stained tumor cells (0–100) as previously re-
ported [25]. The result of multiplying staining intensity
by positive cell percentage is the H-score value, ranging
from 0 to 300. TMA cores were scored for RANK and
RANKL with the assistance of the breast cancer patholo-
gists from the Bellvitge Hospital, if tumor cells repre-
sented > 15% of the total TMA core area. Patients were
stratified according to RANK or RANKL H-scores as
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being protein-positive (H-score ≥ 1) or protein-negative
(H-score = 0). Breast tumors from patient-derived xeno-
grafts were used as positive and negative controls. Ex-
perimental data from our laboratory in breast cancer
cells and patients’ samples [26] confirmed that cells in
which RANK protein expression is not detected by IHC/
western blot may still respond to RANKL stimulation or
denosumab inhibition [11, 26, 27]. This is probably due
to the “fragility” of the RANK epitope and the limited
sensitivity of the current tools to detect RANK protein
expression. Thus, even with an H-score ≥ 1, we are likely
underestimating samples with a functional RANK signal-
ing pathway.
Statistical analyses were performed with the support of
IDIBELL and Nottingham University Statistical Assess-
ment Services. The ER/PR/HER2 status, grade, and
tumor stage were known for each case included in the
TMAs. Associations between IHC scores and clinico-
pathological parameters were evaluated using Pearson’s
chi-squared test.
Cell lines and cell culture
The cell lines BT474 parental (BT474) and BT474 with
lapatinib resistance (BTLR) were described in [28]. SKBR3
parental (SKBR3) and SKBR3 lapatinib resistant (SKLR)
lines were described in [29]. The cell line HCC1954 was
obtained from ATCC (CRL-2338). BT474 cells were
grown in DMEM + GlutaMAX (Gibco) supplemented
with 2mM L-glutamine (HyClone), 1× penicillin-
streptomycin solution (P/S, Gibco), and 7.5% fetal bovine
serum (FBS, Gibco). SKBR3 cells were grown in McCoy’s
5A + GlutaMAX supplemented with 2mM L-glutamine,
1 mM sodium pyruvate (HyClone), 1× P/S, and 5% FBS.
HCC1954 cells were grown in RPMI medium 1640 + Glu-
taMAX supplemented with 2mM L-glutamine, 1× P/S,
and 5% FBS. The cells were grown at 37 °C in 5% CO2 hu-
midified incubators. For RANKL treatments, cells were in-
cubated in the presence of 100–300 ng/ml of RANKL.
Cell lines were routinely tested for mycoplasma
contamination.
Viral transduction
To ectopically express RANK, the RANK gene (TNFR
SF11A) was cloned into the lentiviral vector pSD-69
(kindly provided by S. Duss and M. Bentires-Alj) under
the control of hPGK promoter. As a control (ctrl), we used
an empty pSD-69 plasmid generated by removing the
BamHI-SalI fragment containing CcdB and CmR genes.
Knockdown of RANK endogenous expression was
achieved by shRNA lentiviral delivery using pGIPZ vectors
containing shRNAs against human RANK (RHS4531,
Dharmacon), and shRNAs sequences #3 (TATCTTCTTC
ATTCCAGCT) and #4 (ATTCTTCCTTGAACTTCCC)
were selected based on their ability to silence RANK
expression. As a control, we used pGIPZ expressing a veri-
fied non-targeting sequence (RHS4346 Dharmacon).
Lentiviruses were prepared in HEK293T cells transfected
with psPAX2 (Addgene #12260) and pMD2.G (Addgene
#12259) by the calcium phosphate method. Virus-
containing supernatants were centrifuged at 1500 rpm for
5min and filtered with 0.45-μm filters (Millipore). The
medium from 1-cm2 production cells was used to infect
2-cm2 recipient cells at roughly 33% confluence, adding
fresh medium (1:1) and 8 μg/ml polybrene (Millipore).
Approximately 90% infection efficiency was verified 3 days
after transduction by detection of GFP expressed from
pGIPZ plasmids. Transduced cells were selected with
1.5 μg/ml puromycin (Sigma), starting 3 days after infec-
tion, and subsequently maintained with 1 μg/ml puro-
mycin in the growth media.
Cell proliferation
To determine cell proliferation, 1000–4000 cells per well
in 100 μl were seeded in 96-well plates. After 24 h,
100 μl of medium with or without the indicated concen-
trations of lapatinib (0–16 μM) was added, and cells
were incubated for 4 days. The relative number of viable
cells each day was determined by adding 50 μl of diluted
CCK-8 reagent according to the manufacturer’s protocol
(Sigma).
Western blot
Cells were seeded at approximately 33% confluence in 6-
well plates. The following day, they were washed and in-
cubated in a medium without FBS. The next day, the
medium was changed to 1.8 ml medium with or without
1 μM lapatinib followed by a 2-h incubation. Subse-
quently, 0.2 ml of medium with or without 300 ng/ml of
RANKL (RANKL-LZ Amgen) was added to the wells.
Ten minutes later, the extracts for immunoblots were
prepared with modified RIPA buffer (50 mM Tris pH
7.4, 150 mM NaCl, 1% NP-40, 0.25% sodium deoxycho-
late) containing 1× PhosSTOP and complete protease
inhibitor cocktail (Roche), and protein concentrations
determined with DC protein assay reagents (BIO-RAD).
Fifteen micrograms of protein were resolved by SDS-
PAGE and blotted into Immobilon-P 0.45 μm membranes
(Millipore). Antibodies against the following proteins were
used for probing: RANK (R&D Systems AF683), p-HER2
(#2249), HER2 (#2165), p-EGFR (#3777), EGFR (#4267),
p-ERK1/2 (#9101), ERK1/2 (#9102), p-AKT (#4051), AKT
(#9272), p-p65 (#3033), p65 (#8242), p-IκB (#9246), IκB
(#9242) (from Cell Signaling), β-actin (sc-47778), and
tubulin (Abcam ab21058).
Immunoprecipitation
Upon transiently transfecting HEK293 cells with affinity-
tagged versions of full-length RANK (RANK-V5 in
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pLenti6/V5-DEST, Invitrogen), full-length HER2 (FLAG-
HER2 [30]), an amino (742-NTF) [30], or carboxy-
terminal fragment of HER2 (611-CTF) [31], cells were
washed twice with ice-cold PBS and proteins were ex-
tracted with 20mM Tris-HCl pH 7.4, 137 mM NaCl, 2
mM EDTA, 10% glycerol, 1% NP-40 supplemented with
50 μg/ml leupeptin, 50 μg/ml aprotinin, 0.5 mM sodium
orthovanadate, and 1 mM phenylmethylsulfonyl fluoride.
Equal amounts of extracts were incubated for 3 h with
immunoglobulin G (Abcam ab171870), FLAG (Sigma
F3165), HA (Abcam ab9110), V5 (Thermo Scientific
#R961-25), HER2 (32H2 in house antibody described in
[32]), or trastuzumab (Hoffmann-La Roche) antibodies.
Then, protein A agarose beads (Calbiochem IP02) were
added for 2 h. Immunoprecipitates were washed thor-
oughly with lysis buffer and boiled in reducing SDS
loading buffer to be analyzed by Western blot.
RNA isolation and RT-qPCR
Cells were seeded at approximately 33% confluence in 6-well
plates. The next day, the medium was changed to medium
with or without 100 ng/ml RANKL followed by an additional
24 h incubation period. To analyze mRNA expression levels,
total RNA was purified with Maxwell RSC simplyRNA Tis-
sue kit (AS1340 Promega). For each sample, cDNA was ret-
rotranscribed from 1 μg of RNA using 200U SuperScript II
plus random hexamer oligos following the manufacturer’s
protocol (Invitrogen); cDNA from 20 ng RNA for each sam-
ple was analyzed by SYBR green real-time PCR (Applied Bio-
systems) with 10 μM primers using a LightCycler® 480
thermocycler (Roche). Analyses were performed in triplicates
using the LightCycler® 480 software (Roche). Peptidylprolyl
isomerase A, PP1A, was used as the reference gene. The
primer sequences used in the analyses are as follows: PP1A
(fw ATGGTCAACCCCACCGTT, rev TCTGCTGTCT
TTGGGACCTTG), RANK (fw GCAGGTGGCTTTGCAG
AT, rev 5’GCATTTAGAAACATGTACTTTCCTG), BIRC3
(fw GGTAACAGTGATGATGTCAAATG, rev TAACTG
GCTTGAACTTGACG), ICAM1 (fw AACTGACACC
TTTGTTAGCCACCTC, rev CCCAGTGAAATGCAAA
CAGGAC), TNFα (fw AAGCTGTAGCCCATGTTGT, rev




RANK is expressed in HER2-positive and anti-HER2-
resistant breast cancer patients
The expression of RANK and RANKL in HER2-positive
breast cancer patients was analyzed by immunohisto-
chemistry (IHC) in two independent sets of tissue mi-
croarrays (TMAs): a collection of HER2-positive tumor
samples from treatment-naive patients (n = 197) and a
cohort with tumors resistant to neoadjuvant trastuzumab-
based chemotherapy (n = 43) from patients with residual
invasive disease at surgery.
In the first collection, the integrity of the tissue
allowed scoring of 67 and 72 patients for RANK and
RANKL expression, respectively. Considering positive
those with H-score ≥ 1 for the tumor cells, RANK ex-
pression was found in 14/67 (20.9%) cases and trans-
membrane RANKL staining in just 2/72 (2.8%) of the
samples (Fig. 1a). In the anti-HER2-resistant tumor
samples, we could score 22 patients for RANK and 21
for RANKL (Fig. 1a). In these, 9/22 (40.9%) were positive
for RANK and 2/21 (9.5%) for transmembrane RANKL
in tumor cells (Fig. 1a). Representative pictures of RANK
and RANKL positive samples are shown in Fig. 1b, and
H-scores for the whole tumor core from all samples (ex-
cluding those with integrity issues) and controls are pre-
sented in Fig. S1A and B. Pictures of the whole TMA
core area in both collections are shown in Fig. S2.
Next, we evaluated the clinico-pathological factors as-
sociated with RANK expression in treatment-naive
HER2-positive tumors (Fig. 1c). RANK expression was
significantly associated with tumors from younger pa-
tients (less than 50 years old; p = 0.034) and tumors with
a higher Ki67 proliferation index (p = 0.02). A trend of
increased frequency of RANK expression was found in
ER/PR negative tumors (p = 0.170 and p = 0.090, respect-
ively), and higher histological grade (p = 0.138) (Fig. 1c).
Similar patterns were observed in tumors resistant to
anti-HER2 treatment (Fig. 1c). In both series, the limited
number of samples prevented additional statistically sig-
nificant associations, but general patterns coincided with
those reported in previous studies of RANK/RANKL ex-
pression in human breast cancer samples [11, 12, 33].
Importantly, the frequency of RANK/RANKL-positive
samples was higher in anti-HER2-resistant compared to
treatment-naive HER2-positive tumors.
RANK expression increases after anti-HER2 treatment in
HER2-positive breast cancer patients (PAMELA clinical
trial)
Our previous results suggested that RANK and RANKL
expression may increase upon acquisition of anti-HER2
treatment resistance (Fig. 1a). To determine the possible
changes in RANK and RANKL expression induced by
dual HER2 blockade, gene expression profiling was per-
formed in paired surgical tumor samples obtained before
and following treatment with lapatinib and trastuzumab
(and endocrine therapy if the tumor was hormone
receptor-positive) from the PAMELA phase II clinical
trial [22]. At baseline, the expression of RANK was sig-
nificantly associated with the PAM50 intrinsic subtypes
(Fig. S3A; p < 0.001); non-luminal subtypes (Basal-like
and HER2-enriched) had the highest RANK expression.
No significant differences in RANKL gene expression
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across PAM50 intrinsic subtypes were observed, al-
though RANKL levels were slightly increased in the lu-
minal A subtype (Fig. S3A), as previously reported [33].
Moreover, RANK gene expression was higher in hor-
mone receptor-negative tumor samples (p < 0.001) while
RANKL showed the opposite trend (Fig. 2a) confirming
previous findings [12, 34]. ERBB2 gene expression at
baseline had a weak positive correlation (r = 0.16) with
RANK and the opposite trend (r = − 0.21) with
RANKL expression (Fig. S3B and C). RANK gene ex-
pression increased (Fig. 2b, denoted by red lines in
the left graph and a green line in the right graph) fol-
lowing dual treatment with lapatinib and trastuzumab
(p < 0.001), while RANKL expression did not signifi-
cantly change when analyzing residual disease samples
at surgery (Supplementary Table 1). Specifically, the mean
RANK expression in baseline samples was − 6.22 (standard
deviation (SD) = 1.22) versus − 5.58 (SD = 1.14) in the
Fig. 1 RANK and RANKL are expressed in treatment-naive and anti-HER2-resistant HER2 breast cancer tumor samples. a Frequency of HER2-
positive patients, treatment-naive or anti-HER2-resistant, expressing tumoral RANK or RANKL (H-score ≥ 1). The total number of patients scored for
RANK or RANKL expression is indicated. b Representative images showing RANK and RANKL IHC. c Frequency of tumoral RANK-positive
treatment-naive HER2 or anti-HER2-resistant patients and associations with the indicated clinicopathological parameters including those assessed
by the Nottingham Grading System (histological grade and proliferation determined by mitotic count and Ki67 as detailed in [19]). The total
number of patients analyzed per parameter is indicated in each case. In a and c, two-sided chi-square p values are shown when p < 0.1. n.s.,
non-significant (see also Fig. S1A)
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Fig. 2 (See legend on next page.)
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paired surgical samples. In contrast, the mean RANKL ex-
pression in the baseline samples was − 7.36 (SD = 1.28)
versus − 7.44 (SD = 1.33) in the surgical samples. When
populations were studied separately according to hormone
receptor expression, the same findings were observed, an
increase in RANK mRNA expression in both hormone re-
ceptor positive and negative HER2+ tumors after HER2
inhibition (Fig. S4A and B).
These results confirmed that RANK expression in-
creases in HER2-positive breast tumors after dual HER2
blockade. The increased levels of RANK observed in pa-
tients upon anti-HER2 treatment suggest that activation
of RANK signaling may allow survival of HER2-positive
tumor cells and contribute to resistance to anti-HER2
therapies.
RANK signaling is upregulated after short-term lapatinib
treatment and in HER2-resistant cell lines
As RANK expression increased after dual lapatinib/tras-
tuzumab treatment in HER2-positive breast cancer pa-
tients, we decided to test whether in vitro short-term
treatment with both anti-HER2 drugs, alone or in com-
bination, would influence RANK expression in three dif-
ferent HER2-positive breast cancer cell lines. While
SKBR3 and BT474 cells are sensitive to lapatinib and
trastuzumab, HCC1954 cells are less sensitive to lapati-
nib and resistant to trastuzumab [35].
Lapatinib treatment, alone or in combination with
trastuzumab, resulted in higher RANK mRNA expres-
sion in SKBR3 when compared with non-treated cells
(Fig. 3a). Lapatinib or trastuzumab treatment, as well as
their combination, also increased RANK expression
levels in BT474 cells. In HCC1954 cells, RANK expres-
sion increased with lapatinib alone or in combination
treatment after 12 h, whereas trastuzumab alone did not
alter RANK expression levels. Also, we analyzed RANK
expression in SKBR3 cells, either parental (sensitive to
lapatinib and trastuzumab) or resistant to trastuzumab
(SKTR), to lapatinib (SKLR), or to both (SKTLR and
SKLTR; derived from SKTR and SKLR, respectively)
[29]. RANK gene and protein expression levels were sig-
nificantly higher in lapatinib-resistant SKLR and dual
lapatinib/trastuzumab-resistant SKLTR cells when com-
pared to SKBR3 parental cells (Fig. 3b, c). Increased
RANK mRNA expression was also observed in BT474
cells with acquired lapatinib resistance (LR) when com-
pared to lapatinib-sensitive parental cells according to
public datasets, platform ID: GPL570 [36]; (Fig. 3d), an
increase we verified by RT-qPCR (Fig. 3e).
To confirm that the elevated RANK expression levels
were accompanied by increased activation of the RANK
signaling pathway, the expression of RANK downstream
gene targets BIRC3, ICAM1, TNFα, and IL8, indicative
of NF-κB pathway activation [37, 38], was analyzed in
sensitive and lapatinib-resistant (LR) cells treated with
or without RANKL. Lapatinib-resistant SKLR cells
showed higher gene expression levels of RANK, BIRC3,
ICAM1, TNFα, and IL8 compared with control SKBR3
cells, and their levels were further increased after path-
way stimulation with RANKL, except for IL8 (Fig. 3e). In
lapatinib-resistant BTLR, increased expression of RANK
and its downstream targets ICAM1 and IL8 was de-
tected, and their levels increased further upon RANKL
stimulation compared to sensitive BT474 cells. In these
cells, BIRC3 expression did not change whereas TNFα
was barely expressed (Fig. 3e).
Taken together, RANK expression increased after dual
treatment with lapatinib and trastuzumab in HER2-
positive human breast cancer cell lines, mimicking the
results seen in breast cancer samples from the PAMELA
trial (Fig. 2b). Additionally, two HER2-positive cell lines
(SKBR3 and BT474) with acquired resistance to lapatinib
(SKLR and BTLR) showed increased expression of
RANK and several downstream targets, when compared
to their respective parental controls (Fig. 3b–e).
RANK overactivation increases NF-κB signaling and
resistance to lapatinib
To verify that RANK plays a direct role in the cellular
response to lapatinib, we studied the consequences of
RANKL stimulation and RANK loss in control and
lapatinib-resistant SKBR3 cell lines. A small increase in
lapatinib tolerance was observed in SKLR but not SKBR3
cells in the presence of RANKL (Fig. S5A). RANK silen-
cing with two specific shRNAs reduced lapatinib resist-
ance in SKLR cells, although sensitivity was not fully
restored to the levels observed in WT cells (Fig. 4a, b).
These results indicate that the activation of RANK sig-
naling contributes to lapatinib resistance; however, it is
not the only mechanism responsible for the emergence
(See figure on previous page.)
Fig. 2 RANK, but not RANKL, expression increased after dual anti-HER2 therapy in patient samples (n = 151) from the PAMELA trial. a Box plots of
RANK and RANKL gene expression in HER2-positive tumors at baseline classified by hormone receptor expression. b Ladder plots (on the left)
show the RANK and RANKL gene expression in PAMELA HER2-positive tumors before (baseline) and after (surgery) dual anti-HER2 treatment. An
increase in gene expression is represented in red and a decrease in blue. Each line represents a tumor sample from one patient. p values in
a were calculated by comparing the mean values between both groups and in b were determined by paired two-tailed t tests. Density plots
(on the right) showing the RANK and RANKL gene expression in PAMELA HER2-positive tumors before (baseline) and after (surgery) treatment
(see Fig. S3, S4, and Supplementary Table 1 for further analyses)
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of resistance in SKLR cells. This is in line with the mul-
tiple anti-HER2 resistance mechanisms reported for
these cells [39–41].
Increased IκB and p65 phosphorylation was observed
in lapatinib-resistant SKLR compared to SKBR3 cells
upon RANKL stimulation (Fig. 4c, Fig. S5B and C), con-
firming the elevated NF-κB signaling in lapatinib-
resistant cells. As expected, RANKL-induced NF-κB acti-
vation was abrogated upon RANK silencing in SKLR
cells. RANKL treatment did not significantly alter the
Fig. 3 RANK expression increased in HER2-positive breast cancer cell lines after treatment with anti-HER2 therapies as well as in anti-HER2-
resistant cells. a RANK gene expression levels determined by RT-qPCR in the indicated HER2-positive cell lines after short-term treatment with
lapatinib (Lapa), trastuzumab (Trastu), or the combination of both, relative to corresponding untreated cells (Ctr). Quantifications were performed
in triplicates from two independent experiments. b RANK gene expression levels determined by RT-qPCR in SKBR3 cell lines resistant to
trastuzumab (SKTR), lapatinib (SKLR), or both drugs (SKTLR, SKLTR) compared to sensitive SKBR3 parental cells. Quantifications were performed in
triplicates from at least three independent experiments. c RANK protein expression in parental SKBR3 cells (SK) or resistant to trastuzumab (SKTR),
lapatinib (SKLR), or both (SKLTR). β-Actin was used as a loading control. Blots shown are representative of those obtained from 3 independent
experiments. d RANK gene expression levels in BT474 cells, either control or resistant to lapatinib (LR, according to public datasets [36]). a.u.,
arbitrary units. e RANK and RANK/NF-κB downstream gene targets BIRC3, ICAM1, TNFα, and IL8 mRNA levels relative to housekeeping gene PP1A in
parental (SKBR3, BT474) and lapatinib-resistant (SKLR, BTLR) HER2-positive cell lines with or without RANKL treatment (24 h). Gene expression
levels were quantified by RT-qPCR. PP1A expression was used as an internal reference gene (a, b, e). Determinations were done in triplicates, and
the mean values are depicted from n ≥ 2 independent analyses. p values were calculated by ordinary one-way ANOVA (a, b) and by unpaired
t tests (d) (*≤ 0.05; **≤ 0.01, ***≤ 0.001; n.s., non-significant)
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phosphorylation status of AKT nor ERK in SKBR3,
SKLR, and the RANK-silenced cells (Fig. 4c, S5B and C).
After lapatinib treatment, HER2, AKT, and ERK1/2 pro-
tein phosphorylation levels were undetectable in all cell
lines, but baseline phosphorylation of p65 and IκB was
maintained (Fig. 4c, S5B and C), demonstrating that NF-
κB activation is not dependent on ErbB signaling and
may support the survival of HER2-positive breast cancer
cells in the presence of lapatinib.
To test if RANK signaling and enhanced NF-κB activa-
tion may directly contribute to resistance, we stably
transduced HER2-positive cell lines with RANK overex-
pressing (psD69-RANK) and empty control (psD69-
empty) vectors. RANK overexpression was confirmed by
increased RANK mRNA levels (Fig. 5a) and induction of
NF-κB downstream targets (BIRC3, ICAM1, TNFα, and
IL8) in SKBR3, BT474, and HCC1954 cells (Fig. 5b).
These RANK-overexpressing cell lines showed enhanced
expression of all NF-κB targets analyzed after RANKL
treatment compared to the corresponding parental cells
(Fig. 5b). Next, we tested whether increased activation of
RANK signaling would alter the cell response to lapati-
nib; RANKL stimulation of control cells (empty) did not
alter lapatinib sensitivity (Fig. 5c). In contrast, RANK
overexpression coupled with RANKL treatment resulted
in an increased resistance to lapatinib in all HER2-
Fig. 4 RANK knockdown slightly resensitizes SKLR cells to lapatinib. a The expression levels of RANK mRNA in lapatinib-resistant SKLR cells stably
transduced with non-targeting (control) or two independent RANK knock-down (sh#3 and #4) vectors. RANK expression values were quantified by
RT-qPCR relative to PP1A gene expression. Quantifications were performed in triplicates. b Relative number of living (relative survival) cells stably
transduced with control (SKBR3 and SKLR), sh#3 or sh#4 (SKLR) and incubated for 4 days with the indicated concentrations of lapatinib. Cells were
seeded in growth media; 24 h later lapatinib was added and cells were analyzed with CCK8 as detailed in the “Methods” section. The mean
values and SD of four independent experiments are shown. For each experiment, data was obtained from quintuplicates. Paired t tests were
done between the groups, and the two-tailed p value is depicted (**). In accordance with the lower expression of RANK achieved, sh#3
significantly reduced survival compared to SKLR control cells at 0.063 (p = 0.0097), 0.125 (p = 0.0055), and 0.25 (p = 0.0003) μM of lapatinib. For
sh#4, a significant reduction in survival was observed at 0.125 μM of lapatinib (p = 0.014). The significance of relative survival was calculated for
each concentration using two-tailed p values for one sample t test. c Western blot showing the levels of NF-κB (p-p65, p-IκB) and HER2 (p-HER2,
p-ERK1/2, p-AKT) pathway activation in control SKBR3, lapatinib-resistant SKLR, and sh#3 SKLR cells treated with RANKL or lapatinib. Cells were
serum-starved for 12 h and then treated with lapatinib (2 h) or RANKL (10 min) before processing them. Tubulin was used as a loading control
(see Fig. S5B for total protein levels and Fig. S5C for relative quantifications)
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Fig. 5 (See legend on next page.)
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positive cell lines tested (Fig. 5c), and this effect was ab-
rogated by the RANKL inhibitor denosumab as expected
(Fig. S6A).
We then analyzed RANK downstream signaling in
these cell lines after treatment with lapatinib and/or
RANKL. p65 was strongly phosphorylated in RANK-
overexpressing cell lines upon RANKL treatment and in
parental HCC1954 cells fitting with the higher RANK
expression levels of these cells (Fig. 5d, Fig. S6B and
C). Phosphorylation of p65 was not affected by lapati-
nib treatment. ERK1/2 phosphorylation levels in-
creased after RANKL treatment to a greater extent in
the RANK-overexpressing cells compared to control
ones (Fig. 5d, Fig. S6B and C). AKT phosphorylation
increased after RANKL stimulation in all cells irre-
spectively of RANK levels. Interestingly, RANKL-me-
diated activation of ERK1/2 and AKT in SKBR3 and
BT474 cells overexpressing RANK was completely ab-
rogated in the presence of lapatinib, meaning that
ErbB signaling is required for RANK/RANKL-driven
activation of ERK and AKT in these cells. In
HCC1954 cells, AKT phosphorylation was also abol-
ished by lapatinib. In contrast, the increased p-ERK
levels upon RANKL stimulation in HCC1954 RANK-
overexpressing cells were not affected by lapatinib
(Fig. 5d, Fig. S6B and C).
In summary, enhanced RANK signaling in HER2-
positive cells led to higher NF-κB activation and in-
creased lapatinib resistance.
RANK and HER2 physically and functionally interact
To investigate whether RANK/RANKL activation of
ERK and AKT might take place, at least partially, via dir-
ect crosstalk with ErbB receptors, we compared the
phosphorylation levels of HER2 in cells with and without
RANK overexpression upon RANKL stimulation. RANK
overexpression led to higher levels of p-HER2 in SKBR3
and BT474, but not in HCC1954 cells, compared with
the corresponding controls (Fig. 5d, Fig. S6B and C). Im-
portantly, in all HER2-positive cell lines, concomitant
RANK overexpression and stimulation with RANKL re-
sulted in decreased HER2 phosphorylation, indicating
that RANKL might impinge on the HER2/ErbB signaling
pathway (Fig. 5d).
To further study the putative crosstalk between RANK
and ErbB signaling, we analyzed NF-κB and ErbB signal-
ing after stimulation with ErbB ligands in RANK-
overexpressing HER2-positive cell lines and correspond-
ing controls at different time points. A slight increase in
p65 phosphorylation was observed in SKBR3 and BT474
RANK-overexpressing cells compared with control cells
(Fig. S7). EGF stimulation faintly increased p-p65 levels
in HER2-positive cell lines, but this was not observed
after heregulin (HRG) treatment (Fig. S7). As extensively
reported [42], treatment with EGF and HRG efficiently
induces ERK phosphorylation in all HER2-positive cell
lines (Fig. S7), but no clear differences were observed be-
tween RANK-overexpressing cells and corresponding
controls. Of note, 5 min after ErbB ligand stimulation,
pERK levels are higher but a decrease in HER2 phos-
phorylation was observed, accompanied by less pERK
and pHER2 after 10 min of ErbB ligand stimulation
(Fig. S7). Thus, the reduced HER2 phosphorylation ob-
served in RANK-overexpressing cells 10min after RANKL
stimulation may reflect previous activation of HER2/ERK
signaling.
Due to the change in HER2 phosphorylation upon ac-
tivation of RANK signaling with RANKL, we hypothe-
sized that the two receptors might physically interact.
To enable efficient immunoprecipitation and detection,
we transiently co-expressed affinity-tagged versions of
the receptors in HEK293 cells, including an amino (742-
NTF) [30] and a carboxy-terminal fragment of HER2
(611-CTF) [31]. As shown in Fig. 6a, RANK-V5 was de-
tected after immunoprecipitation of HER2 or 611-CTF
HER2, but not in 742-NTF or any of the control samples
(IgG), indicating that RANK interacts with the carboxy-
terminal region of HER2. The reverse immunoprecipita-
tion of RANK-V5 corroborated these results (Fig. 6b).
To confirm the interaction between the two receptors
(See figure on previous page.)
Fig. 5 Overactivation of RANK signaling in HER2-positive cell lines increased NF-κB activation and lapatinib resistance. a Expression levels of RANK
mRNA in HER2-positive SKBR3, BT474, and HCC1954 cells stably transduced with control (empty) or RANK-overexpressing (RANK) vectors. RANK
expression values were quantified by RT-qPCR relative to PP1A gene expression. Experiments were performed in triplicates and standard error is
depicted. b Expression levels of RANK/NF-κB downstream gene targets BIRC3, ICAM1, TNFα, and IL8 relative to PP1A gene expression in cells
described in a, with and without RANKL treatment (24 h). Experiments were performed in triplicates and standard error is depicted. c Relative
number of living (relative survival) SKBR3, BT474, and HCC1954 cells stably transduced with control (empty) or RANK-overexpressing (RANK)
vectors incubated for 4 days with the indicated concentrations of lapatinib and/or stimulated with RANKL. Cells were seeded in growth media
with/without 100 ng/ml RANKL; 24 h later, lapatinib was added and cells were analyzed with CCK8 after 4 days as detailed in the “Methods”
section. A representative experiment out of three independent experiments is shown. For each experiment, data was obtained from triplicates
and SD, and a two-way ANOVA p value is included. d. Western blot analyses of NF-κB (p-p65) and HER2 (p-HER2, p-ERK1/2, and p-AKT) pathway
activation in cells depicted in c. Before collecting the cells, they were cultured in media without FBS for 12 h and pretreated with/without
lapatinib for 2 h followed by 10min stimulation with RANKL. Representative blots from three independent experiments are shown. Tubulin was
used as a loading control (see Fig. S6B for total protein levels, Fig. S6C for quantifications and Fig. S7 for EGF/HRG stimulations)
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under endogenous expression levels in the context of
breast cancer, we chose SKBR3 cells that, compared to
other breast cancer cell lines, express higher levels of
HER2 and intermediate/lower levels of RANK and do
not express EGFR [43]. HER2 was immunoprecipitated
with the antibody trastuzumab (HCP) that binds to the
HER2 extracellular domain, and the presence of RANK
in the immunoprecipitate was tested by Western blot-
ting. As seen in Fig. 6c, trastuzumab precipitated en-
dogenous RANK demonstrating that the two receptors
physically interact in breast cancer cells in an EGFR-
independent manner.
Discussion
A crosstalk between RANK and EGFR signaling has
been described in the context of osteoclast differenti-
ation [44], as well as in breast cancer for a particular
RANK truncated isoform [45]. In the mammary gland,
we found that pharmacological inhibition of RANKL de-
creases tumorigenesis and lung metastases in the
MMTV-ErbB (Neu) transgenic mouse model [9]. In the
same line, MMTV-ErbB mice with a heterozygous
RANK deletion showed decreased pulmonary metastasis
than RANK WT MMTV-ErbB controls [15]. In addition,
RANKL treatment increased lung metastases in both
Fig. 6 Co-immunoprecipitation of RANK and HER2. a Immunoprecipitation (IP) against HER2 was performed in HEK293 cells transfected with RANK-V5
and HER2, HER2-FLAG, a carboxy-terminal fragment of HER2 (611-CTF) or an amino-terminal fragment of HER2 (742-NTF). IP was performed using anti-
FLAG, anti-HA, or control IgG antibodies as indicated. RANK was detected by blotting the immunoprecipitates (IP, left upper panel) or the whole lysates
(input, right upper panel) with the V5 antibody. HER2 was detected in IPs (left lower panel) and input (right lower panel) using the 32H2 antibody that
detects all forms of HER2. b IP against RANK-V5 was performed in HEK293 cells transfected with RANK-V5 and GFP, HER2-FLAG, a carboxy-terminal
fragment of HER2 (611-CTF) or an amino-terminal fragment of HER2 (742-NTF) using the V5 antibody. In the IP and input, HER2 was detected using the
32H2 antibody. c IP against endogenous HER2 was performed in SKBR3 cells using trastuzumab (Herceptin-HCP) or a control IgG. Endogenous RANK
and HER2 were detected in IP (RANK immunoprecipitated by HER2 is indicated by an asterisk (*) in the upper panel) and input samples
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FVB/N and MMTV-ErbB animals [15]. More recently, a
review [46] followed by an article with experimental data
[47], suggested the combination of RANK and HER2 sig-
naling inhibition as a new strategy for the treatment of
HER2-positive breast carcinomas.
In this study, we have shown that RANK gene expres-
sion increased after dual treatment with lapatinib and
trastuzumab in HER2-positive tumor samples from the
PAMELA clinical trial [22] and in HER2-positive breast
cancer cell lines. These observations would point to in-
creased RANK signaling in patients treated with anti-
HER2 drugs. We also observed that the percentage of
patients with RANK tumor expression doubled in the
context of HER2 resistance when compared to
treatment-naive HER2-positive breast tumors. Further-
more, both SKBR3- and BT474 HER2-positive cell lines
with acquired lapatinib resistance displayed increased
RANK expression and pathway activation compared to
their respective lapatinib-sensitive controls. Thus, our
combined analyses of HER2-positive breast cancer sam-
ples and cell lines demonstrate that RANK expression is
higher in HER2-resistant breast cancer. RANK loss mod-
erately sensitized lapatinib-resistant cells to the drug,
and overactivation of RANK signaling increased lapati-
nib resistance in HER2-positive cell lines (SKBR3,
BT474, and HCC1954). Based on these results, one
could speculate that activation of RANK signaling may
allow breast cancer cells to survive anti-HER2 therapies
and the benefit of combining denosumab with HER2 in-
hibitors as postulated by [47].
NF-κB signaling has been shown to enhance ErbB2-
induced tumor growth both in vitro and in immune-
competent mice [48, 49]. Increased NF-κB activation
downstream of RANK [50] may also contribute to lapati-
nib resistance. Hyperactive NF-κB signaling has been
proposed as a possible resistance mechanism after lapati-
nib treatment in HER2-positive [51] and triple-negative
breast cancer [52, 53]. In HER2-positive breast cancer,
lapatinib-resistant cells show increased NF-κB levels and
do not respond to single HER2 or NF-κB inhibitors, but
to a combination of both [51]. The NF-κB expression is
normally linked to invasive high-grade tumors, and sev-
eral NF-κB inhibitors are currently being investigated
[54, 55]. Chen and colleagues showed that lapatinib
treatment induced a constitutive activation of NF-κB
through Src-dependent p65 and IκBα phosphorylation,
sensitizing the cells to proteasome inhibitors [52]; our
data suggest that increased RANK being a well-known
regulator of NF-κB may also play a role, although we
cannot discard the contribution of other RANK-driven
downstream pathways. The phosphorylation of IκBα,
leading to its degradation and resulting in p50/p65 het-
erodimer nuclear translocation, is mediated by the IKK
complex (comprising IKKα, IKKβ, and IKKγ/NEMO)
[56, 57]. HER2 itself was shown to activate NF-κB via
the canonical pathway involving IKKα in HER2-positive
and ER-negative breast cancer cells [58]. IKKα also me-
diates NF-κB activation in mammary cells during preg-
nancy and after RANKL stimulation [59]. In our study,
we did not observe clear changes in p65 phosphorylation
after stimulation with ErbB ligands and the treatment
with lapatinib could not counteract p65 phosphorylation
driven by RANKL treatment in RANK-overexpressing
HER2-positive cell lines, providing an alternative survival
path for these cells.
Importantly, we have shown RANK binding to HER2
by co-immunoprecipitation experiments. Accordingly,
Zoi et al. recently showed the interaction of RANK with
ErbB family members by proximity ligation assays [47].
In this publication, the authors claim that the number of
RANK/HER2 dimers in cells correlates with HER2 ex-
pression levels. Also, denosumab, trastuzumab, and/or
pertuzumab treatment reduces the number of RANK/
HER2 dimers whereas RANKL stimulation leads to an
increased number of RANK/HER2 dimers [47]. Finally,
their data show that RANKL addition decreases the effi-
cacy of HER2 inhibitors [47]. In our hands, a direct
interaction between RANK and HER2, independent of
EGF, was observed. RANKL stimulation of HER2-
positive breast cancer cells overexpressing RANK de-
creases HER2 phosphorylation, indicating that RANKL
influences ErbB2 signaling.
RANKL was shown to promote migration in breast
cancer cells after activation of the ERK and AKT path-
ways [60]. We have also found increased phosphoryl-
ation of ERK1/2 and AKT after RANKL treatment in
SKBR3 and BT474 cell lines, with either physiological or
increased RANK levels by receptor overexpression.
Interestingly, we observed that RANKL-mediated induc-
tion of ERK1/2 and AKT phosphorylation was com-
pletely abrogated after lapatinib treatment in SKBR3 and
BT474 cells, again independently of RANK receptor ex-
pression levels. These observations and the fact that
RANK and HER2 interact suggest that lapatinib inhibits
not only EGFR/HER2 tyrosine phosphorylation but also
RANK signaling driven by RANKL (e.g., ERK1/2 and
AKT). Importantly, in addition to the direct interaction
between RANK and HER2, we observed that RANK sig-
naling is functionally linked to the ErbB2 pathway. Add-
itional research is required to address whether the direct
RANK/HER2 interaction contributes to the enhanced re-
sistance to lapatinib observed after activation of RANK
signaling.
Taken together, we showed that anti-HER2 treatment
and resistance acquisition both raised RANK expression
levels in HER2-positive clinical breast tumors and cell
lines. Also, enhanced RANK signaling increased lapati-
nib resistance in HER2 breast cancer cells. We found
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that RANK and HER2 physically and functionally inter-
act. Altogether, these results hint to a dual RANK and
HER2 inhibition therapy for RANK-expressing HER2-
positive breast cancer patients, whose benefit remains to
be tested.
Conclusions
In summary, we showed that RANK is expressed in
HER2-positive breast cancer samples, particularly in pa-
tients resistant to anti-HER2 blocking therapy. The
RANK expression is often associated with younger age,
hormone receptor-negative status, and higher histo-
logical grade and proliferation index. Moreover, in
HER2-positive breast cancer samples from the PAMELA
trial, RANK expression increased upon treatment with
lapatinib and trastuzumab. This was confirmed in vitro
in several HER2-positive human breast cancer cell lines
suggesting that RANK signaling may contribute to the
development of lapatinib resistance. Indeed, RANK-
overexpressing HER2-positive cell lines showed in-
creased resistance to lapatinib and higher NF-κB path-
way activation. Finally, we demonstrated that RANK
physically and functionally interacted with HER2 sug-
gesting a RANK/HER2 crosstalk. Together, these results
suggest that inhibition of RANK signaling may improve
the response to anti-HER2 therapies in RANK-positive,
HER2-positive breast cancer patients.
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Additional file 1: Figure S1. TMA H-scores and controls. A. RANK and
RANKL H-scores in HER2-positive breast cancer samples, treatment-naïve
(left panels) or anti-HER2-resistant (right panels). In treatment-naïve TMAs,
each number represents a “core” from a single patient. In anti-HER2-
resistant TMAs, scored independent tumor cores are numbered for each
patient (after the symbol #). B. Representative pictures of human breast
tumors from patient-derived xenografts used as positive and negative
controls for RANK and RANKL IHC.
Additional file 2: Figure S2. RANK and RANKL staining in TMAs. A.
Pictures of RANK and RANKL protein expression analyzed by IHC in the
TMA cores from the treatment-naïve cohort. B. Pictures of RANK and
RANKL protein expression analyzed by IHC in the TMA cores from the
anti-HER2 resistant cohort.
Additional file 3: Figure S3. RANK and RANKL expression in breast
cancer samples from the PAMELA clinical trial. A. Expression of RANK and
RANKL across the intrinsic molecular subtypes from the PAMELA study. P
values were calculated by comparing mean values across all groups. B.
Scatter plots of RANK and RANKL expression versus ERBB2 expression for
baseline samples in the PAMELA study. Solid line in each figure
represents the regression line. Pearson correlation coefficient (r) with
significance (p value) is presented in each figure. C. Pearson correlation
between single genes and gene expression signatures evaluated in
baseline samples from the PAMELA study.
Additional file 4: Figure S4. RANK but not RANKL expression increased
after dual anti-HER2 therapy in HR+ and HR- patient samples (n = 151)
from the PAMELA trial. A and B. Ladder plots (left panels) showing RANK
and RANKL gene expression in PAMELA HER2-positive HR+ (A) and HR-
(B) tumors before (baseline) and after (surgery) dual anti-HER2 treatment.
An increase in gene expression is represented in red and a decrease in
blue. Each line represents a tumor sample from one patient. P values in A
were calculated by comparing mean values between both groups and in
B were determined by paired two-tailed t-tests. Density plots (right
panels) showing RANK and RANKL gene expression in PAMELA HER2-
positive HR+ (A) and HR- (B) tumors before (baseline) and after (surgery)
treatment.
Additional file 5: Figure S5. A. Relative number of living (relative
survival) SKBR3 and SKLR control cells incubated for 4 days with the
indicated concentrations of lapatinib and stimulated with RANKL. Cells
were seeded in growth media, 100 ng/ml RANKL were added 24h after
seeding, lapatinib was added 24 h later and cells were analyzed with
CCK8 as detailed in methods. Determinations were done in triplicates,
mean values are depicted from n = 5 independent experiments and SD
and p-value (**) calculated by one-way ANOVA is depicted (p ≤ 0.05 for
SKBR3 vs SKLR and SKLR +RANKL, SKBR3 +RANKL vs SKLR and SKLR
+RANKL; n.s. for SKBR3 vs SKBR3 +RANKL and SKLR vs SKLR +RANKL). Sig-
nificance of relative survival was calculated for each concentration using
two-tailed p values for one sample t test. RANKL significantly increased
survival of SKLR cells at 0.018 μM of lapatinib (p = 0.019). B. Western blot
showing the total levels of IκB, p65, ERK1/2, AKT and HER2 in SKBR3 con-
trol, SKLR control and SKLR sh#3 cells treated with RANKL or lapatinib as
depicted in Fig. 4c. Cells were serum starved for 12 h and then treated
with lapatinib (2 h) or RANKL (10 min) before processing them. Tubulin
was used as a loading control. C. Table depicting the relative phospho-
protein levels of the indicated proteins from the western blots shown in
Fig. 4c and Fig. S5B determined by densitometry analyses with Image J.
Additional file 6: Figure S6. A. Relative number of living (relative
survival) SKBR3 RANK cells stimulated with RANKL in the presence or
absence of denosumab (DNS) and incubated for 4 days with the
indicated concentrations of lapatinib. Cells were seeded in growth media
with/without denosumab (1 μg/ml), lapatinib was added after 24 h
stimulation with 100 ng/ml RANKL, and cell viability was analyzed with
CCK8 as detailed in methods. Determinations were done in triplicates,
mean values from n ≥ 2 independent experiments and SD are depicted.
B. Western blot analyses of total levels of p65, ERK1/2 and HER2 in whole
lysates from SKBR3, BT474 and HCC1954 cells stably transduced with
control (empty) or RANK overexpressing (RANK) vectors as depicted in
Fig. 5d. Before collecting the cells, they were cultured in media without
FBS for 12 h, pretreated with/without lapatinib for 2 h followed by 10 min
stimulation with RANKL. Tubulin was used as a loading control. C. Table
depicting the relative phospho-protein levels of the indicated proteins
from the western blots shown in Fig. 5d and Fig. S6B determined by
densitometry analyses with Image J.
Additional file 7: Figure S7. Western blot analyses of HER2 (p-HER2, p-
ERK1/2) and NF-κB (p-p65) pathway activation in SKBR3, BT474 and
HCC1954 cells stably transduced with empty or RANK overexpressing
(RANK) vectors. Cells were cultured in media without FBS for 12 h,
followed by stimulation with EGF (100 ng/ml) (upper panels) or heregulin
(HRG 10 ng/ml) (lower panels) for the indicated times. Tubulin was used
as a loading control.
Additional file 8: Supplementary Table 1.
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